The LuNGS Alliance, spearheaded by the Cancer Research and Statistic Foundation (CRSF), has launched a free Lung NGS (Next-Generation Sequencing) biomarker testing initiative for lung cancer patients across India. This program, supported by AstraZeneca, Pfizer, and Roche, with 4baseCare as the official lab partner, aims to raise awareness about precision oncology as an affordable and accessible approach to lung cancer treatment.

The TARGT First Solid test by 4baseCare analyzes 72 commonly mutated genes, helping identify actionable biomarkers that guide personalized treatment plans. By detecting mutations linked to FDA and NCCN-approved therapies, oncologists can offer tailored, more effective treatments, improving patient outcomes.

The initiative addresses the gap between innovative cancer care and accessibility by ensuring that financial limitations do not hinder access to advanced treatments. With lung cancer contributing to over 72,000 new cases and 66,000 deaths annually in India, according to The Lancet Regional Health, targeted therapies are crucial in improving survival rates.

Dr. Kumar Prabhash from CRSF emphasized their commitment to making precision oncology accessible and transforming cancer care. Hitesh Goswami, CEO of 4baseCare, highlighted that NGS-based biomarker testing should be a standard for lung cancer patients, bringing the vision of democratizing precision medicine closer to reality.